Market Overview

Bristol-Myers Squibb and Tsinghua University Announce Collaboration to Accelerate Early Research into Potential Therapies for Autoimmune Diseases and Cancer


Squibb Company
(NYSE:BMY) and Tsinghua
, have entered into a collaboration to discover
therapeutic agents against novel targets for autoimmune diseases and
cancers. The collaboration brings together Bristol-Myers Squibb and
Tsinghua University's respective scientific expertise and capabilities
with a focus on validating new targets and generating early drug
candidates for clinical development.

Under the collaboration, The Innovation Center for Immune Therapy of
Tsinghua University will conduct research on projects and Bristol-Myers
Squibb will have an option to exclusively license therapeutic agents
discovered by Tsinghua University.

Professor Chen Dong, director of the Institute for Immunology at
Tsinghua University, said, "As an immunology-based research institution
in China, Tsinghua University ICIT continues to explore an innovative
technology incubation model to transform basic research results into
therapeutic drugs through strategic cooperation. We believe that our
strengthened collaboration with BMS will combine our respective
distinguished expertise in the field of immune diseases, helping
transform research discoveries into new treatment options as soon as

"Bristol-Myers Squibb and Tsinghua University have built a long-term
strategic collaboration and have a shared focus on advancing science and
research to help patients," said Carl Decicco, senior vice president and
Head of Discovery at Bristol-Myers Squibb. "Tsinghua University is a
highly respected research institution with leading capabilities and
scientific talent focused on accelerating basic research into potential
new therapies. We look forward to bringing projects forward that will
benefit from their innovative research in immunology and autoimmune

"BMS is committed to addressing the urgent unmet clinical needs in China
through leading scientific development, diversified collaborations and
an innovative portfolio. This collaboration with Tsinghua University is
another proof of our strategic alignment with China's innovation-driven
healthcare development, as well as our commitment to accelerate
delivering of innovative treatment options to Chinese patients," said
Shirley Zhao, general manager and president of Bristol-Myers Squibb in
mainland China and Hong Kong.

The collaboration is an expansion of an existing relationship between
Bristol-Myers Squibb and Tsinghua University that began in 2012 which
focused on autoimmune target discovery, structural biology research as
well as the science of mapping the 3D protein structure of biological
molecular targets.

About Bristol-Myers Squibb
Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients
prevail over serious diseases. For more information about Bristol-Myers
Squibb, visit us at
or follow us on LinkedIn,
and Facebook.

About Tsinghua University Innovation Center for
Immune Therapy (ICIT)

Tsinghua University Innovation
Center for Immune Therapy (ICIT), a joint entity of the Institutes for
Immunology and Institute of Technology Transfer at Tsinghua University,
was established in August 2016. ICIT aims to accelerate transformation
of basic scientific discoveries into innovative medicines. ICIT thus
serves as an "incubator" for translational research "from target to hit"
by providing seed money as well as technical expertise. The successful
applications are expected to have sound scientific basis and carefully
crafted plan to develop first-in-class lead molecules for immune-related

View Comments and Join the Discussion!